je.st
news
APO-T And LinXis Announce Antibody Drug Conjugate Option To In-License Agreement
2013-03-22 09:08:00| drugdiscoveryonline News Articles
APO-T B.V. and LinXis B.V., both privately owned oncology companies, announced recently that LinXis has granted APO-T an exclusive worldwide license for the development and commercialization of fully-human antibody-drug-conjugates using APO-T’s MAGE-HLA targeted antibodies and LinXis’ unique LX linker technology
Tags: agreement
option
drug
announce
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||